Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases
You may also be interested in...
Novartis Venture Fund Supporting Korea's Bio Start-ups
Series B financing for the fund's first investment is seen by Novartis as validation for discovery efforts.
Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow
SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010
Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow
SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010